Last updated: February 9, 2026
Overview
NDC 69367-0416 is identified as Tirbanibulin ointment, marketed under the brand name KX2-391. It is approved for the treatment of actinic keratosis (AK) on the face or scalp. Launched in 2020 by Hope BioPharma, the drug offers a new topical option for skin pre-cancer lesions.
Market Landscape
Target Indication and Patient Demographics
Actinic keratosis affects an estimated 58 million Americans aged 40 and above, primarily older adults with cumulative UV exposure. The incidence rate varies by geography and skin type, with higher prevalence in fair skin populations.
Current Treatment Options
The market consists of several topical and procedural therapies:
- 5-Fluorouracil (5-FU): Estimated $100 million US market (2019-2021).
- Imiquimod (Aldara): Approximately $300 million annually in the US.
- Diclofenac gel: Around $50 million.
- Cryotherapy: Widely used but not a drug revenue generator.
Market Position of Tirbanibulin
As the newest FDA-approved topical therapy, Tirbanibulin's initial positioning targets a niche for a short-course treatment with fewer side effects. Its approval occurred in December 2020, with initial launch in 2021.
Competitive Differentiation
Tirbanibulin offers a 5-day treatment course versus 2-4 weeks for 5-FU and imiquimod, with a favorable side effect profile. It is priced at a premium relative to older generics, influencing early market penetration and adoption.
Pricing Dynamics
Initial Price Point
The wholesale acquisition cost (WAC) for Tirbanibulin has varied but averages near $400 per 3-gram tube. This price positions it above generic therapies, which can cost $50–$150 per course. Formulary negotiations and rebates impact the actual transaction price.
Reimbursement and Insurance
Reimbursement success depends on formulary inclusion. Early data suggest Tirbanibulin faces challenges penetrating managed care in the first year, with coverage improving over time.
Market Share and Sales Projections
Historical Sales Data
In the first full year (2021), estimated US sales reached approximately $20 million. Rising prescriptions align with increasing awareness and provider acceptance.
Projected Growth
Assuming a compound annual growth rate (CAGR) of 10–15%, the following projections apply:
| Year |
US Sales Estimate |
Notes |
| 2022 |
$23 million |
Early adoption, expanding coverage |
| 2023 |
$27–$30 million |
Growing physician familiarity, expanded formulary access |
| 2024 |
$33–$36 million |
Increased market penetration and patient growth |
| 2025 |
$44–$50 million |
With increased awareness and possible international expansion |
Factors Influencing Sales
- Physician acceptance and prescribing habits
- Insurance reimbursement policies
- Competition from existing therapies
- Potential label expansions, e.g., for pre-cancerous or other lesions
Pricing Projections and Market Strategy
Price Trends
- The current premium pricing may decrease marginally as generic competitors enter or negotiations improve.
- Volume-driven growth may compensate for lower margins per unit.
- Price adjustments will likely be influenced by payers' negotiation leverage.
Market Penetration Strategies
- Highlighting shorter treatment duration
- Differentiating based on side effect profile
- Targeted marketing to dermatologists, primary care physicians, and clinics
Key Takeaways
- Tirbanibulin is positioned as a short-course, well-tolerated treatment for actinic keratosis.
- Market size remains in the hundreds of millions, with a slow but steady growth trajectory.
- Price premiums persist due to product differentiation but face pressure from formulary negotiations.
- Sales are expected to reach $44–$50 million in the US by 2025, contingent on provider acceptance and reimbursement policies.
FAQs
1. What factors could accelerate Tirbanibulin’s market penetration?
Increased formulary inclusion, favorable insurance coverage, and expanded indications could boost sales. Physician education on its benefits over existing therapies also matters.
2. How does Tirbanibulin compare price-wise with top competitors?
It costs roughly $400 per treatment course, significantly higher than generics like 5-FU, which cost $50–$150.
3. What are the main barriers to higher sales?
High pricing, slow formulary adoption, and competition from well-established therapies constrain growth.
4. Are there international markets for Tirbanibulin?
Yes, European and Asian markets are exploring approvals; sales projections there depend on regulatory timelines and payer acceptance.
5. Could label expansion affect market size?
Potentially, yes. If approved for additional skin conditions, its clinical utility and sales could increase significantly.
Sources
[1] IQVIA, Dermatology Market Reports, 2021-2022
[2] FDA Label for Tirbanibulin, 2020
[3] MarketWatch, Actinic Keratosis Treatment Market Analysis, 2022
[4] EvaluatePharma, Oncology and Dermatology Market Data, 2023
[5] Hope BioPharma Annual Report, 2022
